| Rationale behind targeting fibroblast activation protein–expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy WN Brennen, JT Isaacs, SR Denmeade Molecular cancer therapeutics 11 (2), 257-266, 2012 | 261 | 2012 |
| Engineering a prostate-specific membrane antigen–activated tumor endothelial cell prodrug for cancer therapy SR Denmeade, AM Mhaka, DM Rosen, WN Brennen, S Dalrymple, I Dach, ... Science translational medicine 4 (140), 140ra86-140ra86, 2012 | 250 | 2012 |
| Concise review: mesenchymal stem cell-based drug delivery: the good, the bad, the ugly, and the promise TEG Krueger, DLJ Thorek, SR Denmeade, JT Isaacs, WN Brennen Stem cells translational medicine 7 (9), 651-663, 2018 | 232 | 2018 |
| Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth J Lin, MC Haffner, Y Zhang, BH Lee, WN Brennen, J Britton, SK Kachhap, ... The Prostate 71 (4), 333-343, 2011 | 214 | 2011 |
| Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug WN Brennen, DM Rosen, H Wang, JT Isaacs, SR Denmeade Journal of the National Cancer Institute 104 (17), 1320-1334, 2012 | 200 | 2012 |
| Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin AM LeBeau, WN Brennen, S Aggarwal, SR Denmeade Molecular cancer therapeutics 8 (5), 1378-1386, 2009 | 172 | 2009 |
| Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment JT Isaacs, L Antony, SL Dalrymple, WN Brennen, S Gerber, H Hammers, ... Cancer research 73 (4), 1386-1399, 2013 | 117 | 2013 |
| Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites S Aggarwal, WN Brennen, TP Kole, E Schneider, O Topaloglu, M Yates, ... Biochemistry 47 (3), 1076-1086, 2008 | 102 | 2008 |
| Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient‐derived xenograft (PDX) models NM Navone, WM van Weerden, RL Vessella, ED Williams, Y Wang, ... The Prostate 78 (16), 1262-1282, 2018 | 92 | 2018 |
| Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer WN Brennen, S Chen, SR Denmeade, JT Isaacs Oncotarget 4 (1), 106, 2013 | 90 | 2013 |
| Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment WN Brennen, SR Denmeade, JT Isaacs Endocrine-related cancer 20 (5), R269-R290, 2013 | 79 | 2013 |
| Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors Y Zhu, SL Dalrymple, I Coleman, SL Zheng, J Xu, JE Hooper, ... Oncogene 39 (45), 6935-6949, 2020 | 73 | 2020 |
| A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer O Levy, WN Brennen, E Han, DM Rosen, J Musabeyezu, H Safaee, ... Biomaterials 91, 140-150, 2016 | 73 | 2016 |
| Tumor‐infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer? TE Krueger, DLJ Thorek, AK Meeker, JT Isaacs, WN Brennen The Prostate 79 (3), 320-330, 2019 | 68 | 2019 |
| A phase I study to assess the safety and cancer-homing ability of allogeneic bone marrow-derived mesenchymal stem cells in men with localized prostate cancer MT Schweizer, H Wang, TJ Bivalacqua, AW Partin, SJ Lim, C Chapman, ... Stem cells translational medicine 8 (5), 441-449, 2019 | 59 | 2019 |
| Asporin restricts mesenchymal stromal cell differentiation, alters the tumor microenvironment, and drives metastatic progression RM Hughes, BW Simons, H Khan, R Miller, V Kugler, S Torquato, ... Cancer research 79 (14), 3636-3650, 2019 | 55 | 2019 |
| Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer B Kumar, AZ Rosenberg, SM Choi, K Fox-Talbot, AM De Marzo, L Nonn, ... Scientific reports 8 (1), 7189, 2018 | 48 | 2018 |
| Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers RA Sikes, AM Walls, WN Brennen, JD Anderson, I Choudhury-Mukherjee, ... Clinical Prostate Cancer 2 (3), 181-187, 2003 | 39 | 2003 |
| Mesenchymal stem cells and the embryonic reawakening theory of BPH WN Brennen, JT Isaacs Nature Reviews Urology 15 (11), 703-715, 2018 | 37 | 2018 |
| Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)‐activated prodrug in murine xenograft models of human cancer WN Brennen, DM Rosen, A Chaux, GJ Netto, JT Isaacs, SR Denmeade The Prostate 74 (13), 1308-1319, 2014 | 36 | 2014 |
